| Literature DB >> 26884476 |
Agustin Gonzalez-Vicente1, Jagannath H Saikumar2, Katherine J Massey2, Nancy J Hong3, Fernando P Dominici4, Oscar A Carretero2, Jeffrey L Garvin5.
Abstract
Angiotensin II (Ang II) causes nitric oxide synthase (NOS) to become a source of superoxide (O2 (-)) via a protein kinase C (PKC)-dependent process in endothelial cells. Ang II stimulates both NO and O2 (-) production in thick ascending limbs. We hypothesized that Ang II causes O2 (-) production by NOS in thick ascending limbs via a PKC-dependent mechanism. NO production was measured in isolated rat thick ascending limbs using DAF-FM, whereas O2 (-) was measured in thick ascending limb suspensions using the lucigenin assay. Consistent stimulation of NO was observed with 1 nmol/L Ang II (P < 0.001; n = 9). This concentration of Ang II-stimulated O2 (-) production by 50% (1.77 ± 0.26 vs. 2.62 ± 0.36 relative lights units (RLU)/s/μg protein; P < 0.04; n = 5). In the presence of the NOS inhibitor L-NAME, Ang II-stimulated O2 (-) decreased from 2.02 ± 0.29 to 1.10 ± 0.11 RLU/s/μg protein (P < 0.01; n = 8). L-arginine alone did not change Ang II-stimulated O2 (-) (2.34 ± 0.22 vs. 2.29 ± 0.29 RLU/s/μg protein; n = 5). In the presence of Ang II plus the PKC α/β1 inhibitor Gö 6976, L-NAME had no effect on O2 (-) production (0.78 ± 0.23 vs. 0.62 ± 0.11 RLU/s/μg protein; n = 7). In the presence of Ang II plus apocynin, a NADPH oxidase inhibitor, L-NAME did not change O2 (-) (0.59 ± 0.04 vs. 0.61 ± ×0.08 RLU/s/μg protein; n = 5). We conclude that: (1) Ang II causes NOS to produce O2 (-) in thick ascending limbs via a PKC- and NADPH oxidase-dependent process; and (2) the effect of Ang II is not due to limited substrate.Entities:
Keywords: Kidney; NADPH oxidase; protein kinase C; reactive oxygen species; uncoupling
Mesh:
Substances:
Year: 2016 PMID: 26884476 PMCID: PMC4759044 DOI: 10.14814/phy2.12697
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Figure 1Effect of acute angiotensin II (Ang II) treatment on NO production by isolated thick ascending limbs. Tubules were manually dissected, held with pipettes and NO production measured with DAF‐FM. P < 0.001 versus basal; n = 9 for 1 nmol/L Ang II. AFU, arbitrary fluorescence units.
Figure 2Effect of 1 nmol/L Ang II on O2 − production by thick ascending limb suspensions (P < 0.04; n = 5). Lucigenin plus Tiron were used to detect O2 − production in the presence or absence of Ang II.
Figure 3Effect of the NOS inhibitor L‐NAME (1 mmol/L) on Ang II‐induced O2 − in thick ascending limb suspensions (P < 0.01; n = 8). Lucigenin plus Tiron were used to detect Ang II‐stimulated O2 −.
Figure 4Effect of the NOS substrate L‐arginine (100 μmol/L) on Ang II‐induced O2 − in thick ascending limb suspensions (n = 5). Lucigenin plus Tiron were used to detect Ang II‐stimulated O2 −.
Figure 5: Effect of the NOS inhibitor L‐NAME (1 mmol/L) on Ang II‐stimulated O2 − in thick ascending limb suspensions in the presence of the PKC α/β 1 inhibitor Gö 6976 (100 nmol/L)(n = 7). Lucigenin plus Tiron were used to detect Ang II‐stimulated O2 −.
Figure 6Effect of the NOS inhibitor L‐NAME (1 mmol/L) on Ang II‐stimulated O2 − in thick ascending limb suspensions in the presence of the NADPH oxidase inhibitor apocynin (10 μmol/L) (n = 5). Lucigenin plus Tiron were used to detect Ang II‐stimulated O2 −.
Figure 7Ang II‐stimulated O2 − production by NOS requires at least one of these pathways involving NADPH oxidase: (1) NADPH oxidase‐derived O2 − exerts a positive feedback over the PKC α pool stimulated by Ang II (dashed lines); or (2) NADPH oxidase‐derived O2 − stimulating a different pool of PKC α/δ (solid lines). Both pathways converge in the final step which is NOS phosphorylation by PKC.